Clinical Trial Update: Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Campath-1H (alemtuzumab) and rituximab for CD52- and CD20-positive refractory or relapsed chronic lymphoid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Campath-1H (alemtuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2011-02-25